Review: ovarian aging and systemic health, mechanisms and proposed interventions
This review proposes that ovarian aging may contribute to systemic aging through an ovarian-systemic axis, linking cellular defects and estrogen decline to broader physiology, and discusses emerging interventions as possible future strategies. [1]
Automatic summary · not editorially reviewed
The key findings
The review proposes that ovarian aging may contribute to systemic aging via an ovarian-systemic axis. [1]
The review states that ovarian-derived endocrine disruption, especially estrogen decline, broadly affects bodily physiology. [1]
The review suggests ovary-targeted prevention may extend healthspan, assessed by combined reproductive and systemic clinical evaluations. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Ovarian aging and female age-related multimorbidity, as discussed in the review
- Summary based on
- Study abstract
- Original publication
- August 17, 2026
Proposed ovarian-systemic axis in this review
The review outlines a proposed ovarian-systemic axis: ovarian aging may contribute to systemic aging. It describes intrinsic ovarian cellular defects such as genomic instability, epigenetic shifts, and mitochondrial and proteostasis damage. These may trigger a senescence-associated secretory phenotype, called SASP, related to inflammaging, fibrosis and distal pro-aging signals. The authors also state that ovarian aging is possibly associated with female age-related multimorbidity. This is a proposed framework, not a demonstrated causal chain.
Supporting source [1]
Estrogen decline and proposed multimodal interventions
The review states that ovarian-derived endocrine disruption, especially estrogen decline, broadly affects bodily physiology. It summarizes emerging multimodal interventions, including senolytics, metabolic reprogramming, regenerative medicine and systemic approaches. The authors discuss their dual potential to preserve fertility and to intercept ovarian contributions to systemic aging. These are described as emerging strategies, not established treatments.
Supporting source [1]
Healthspan goal and abstract-only scope
The review suggests that ovary-targeted prevention may extend healthspan, as assessed by combined reproductive and systemic clinical evaluations. This is framed as a possibility, not a demonstrated outcome. Only the abstract was reviewed; the full text was not reviewed. The abstract does not report study design details, sample sizes, follow-up or effect sizes, so the strength of the underlying evidence cannot be judged here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a review of proposed mechanisms and emerging interventions, not a primary study. The abstract reports no study design, sample, follow-up or effect sizes, and associations are not causes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Jing Y, Qu J, Wang S, Liu GH. · europepmc.org · August 17, 2026